111, Inc. YI
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.05
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.80B | $1.97B | $2.11B | $1.96B | $1.95B | $1.26B | $567.7M | $259.8M | — |
| Cost of revenue | $1.69B | $1.86B | $1.99B | $1.84B | $1.85B | — | — | — | — |
| Gross profit | $103.4M | $113.6M | $119.6M | $121.8M | $97.5M | — | — | — | — |
| SG&A | $9.9M | $9.7M | $31.6M | $29.8M | $32.5M | $19.7M | $17.7M | $14.4M | — |
| Total operating expenses | $1.80B | $1.97B | $2.15B | $2.01B | $2.05B | $1.33B | $638.6M | $318.0M | — |
| Operating income | -$340.0K | $289.0K | -$49.3M | -$53.8M | -$100.8M | -$72.5M | -$70.9M | -$58.2M | — |
| Interest expense | $5.1M | $3.9M | $2.8M | $1.9M | $861.0K | $1.4M | $520.0K | — | — |
| Pre-tax income | -$3.2M | -$2.8M | -$49.7M | -$54.5M | -$97.5M | -$71.6M | -$72.1M | -$55.6M | — |
| Income tax | $2.0K | $13.0K | $35.0K | $0 | $0 | — | — | $1.0K | — |
| Net income | -$3.2M | -$2.8M | -$49.8M | -$54.5M | -$97.5M | -$71.6M | -$72.1M | -$55.6M | — |
| EPS, basic | -0.05 | -0.05 | -0.33 | -0.36 | -0.63 | — | — | — | — |
| EPS, diluted | -0.05 | -0.05 | -0.33 | -0.36 | -0.63 | -0.42 | -0.44 | -0.56 | — |
| Shares, diluted (wtd. avg.) | $174.0M | $171.8M | $168.6M | $166.6M | $165.9M | $164.8M | $163.7M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $73.1M | $74.1M | $85.4M | $101.0M | $110.3M | $206.9M | $106.9M | $122.6M | $24.4M |
| Short-term investments | $7.2M | — | $7.1M | $29.8M | $28.6M | $46.0M | — | $36.8M | — |
| Receivables | $37.1M | $56.6M | $75.6M | $70.9M | $63.5M | $25.0M | $9.4M | $4.2M | — |
| Inventory | $142.8M | $190.1M | $199.9M | $217.3M | $175.9M | $117.5M | $69.8M | $30.7M | — |
| Total current assets | $303.9M | $363.0M | $413.1M | $469.2M | $439.7M | $440.3M | $212.8M | $219.2M | — |
| Property, plant and equipment | $3.0M | $4.5M | $4.8M | $7.0M | $12.6M | $6.7M | $4.3M | $3.0M | — |
| Other intangibles | $124.0K | $197.0K | $318.0K | $474.0K | $770.0K | $999.0K | $1.2M | $655.0K | — |
| Total assets | $314.6M | $381.9M | $435.1M | $503.7M | $493.6M | $463.8M | $231.3M | $224.9M | — |
| Accounts payable | $183.4M | $235.8M | $223.8M | $255.9M | $211.4M | $164.5M | $63.8M | $30.9M | — |
| Short-term debt | $26.8M | $22.1M | $47.6M | $26.0M | $40.7M | $35.1M | $13.7M | — | — |
| Total current liabilities | $279.4M | $320.9M | $386.6M | $395.1M | $334.2M | $249.8M | $111.1M | $45.7M | — |
| Total liabilities | $284.0M | $329.8M | $396.2M | $409.7M | $360.5M | $259.9M | $120.1M | $46.9M | — |
| Retained earnings | -$564.9M | -$532.1M | -$537.9M | -$496.8M | -$472.3M | -$358.6M | -$270.5M | -$201.3M | — |
| Total equity | -$100.4M | -$88.0M | -$82.2M | -$60.1M | -$27.2M | $54.8M | $111.6M | $178.1M | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $17.0M | $36.0M | -$63.0M | -$3.4M | -$108.1M | -$17.9M | -$73.6M | -$49.9M | — |
| Depreciation and amortisation | $1.7M | $2.3M | $3.1M | $5.9M | $4.3M | $2.1M | $1.7M | $1.6M | — |
| Stock-based compensation | $1.4M | $2.8M | $31.9M | $23.5M | $22.8M | $11.6M | $7.8M | $7.5M | — |
| Capital expenditure | $636.0K | $2.1M | $1.4M | $4.6M | $9.8M | $3.9M | $2.9M | $2.1M | — |
| Investing cash flow | -$7.7M | $5.1M | $21.4M | -$6.8M | $9.4M | -$49.8M | $34.1M | $6.5M | — |
| Financing cash flow | -$3.0M | -$55.7M | $29.0M | $3.3M | $11.7M | $164.0M | $15.7M | $141.5M | — |
| Buybacks | — | — | — | — | $924.0K | $1.8M | $3.3M | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-052002.
Others in SIC 5912
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| CVS | CVS HEALTH Corp | $123.73B | 69.6x | 7.8% |
| PETS | PETMED EXPRESS INC | $39.2M | — | -21.1% |
| GRDN | Guardian Pharmacy Services, Inc. | — | — | 17.9% |
| RDGT | Ridgetech Inc. | — | — | 10.2% |